The present invention relates to a process for producing a solid pharmaceutical composition comprising the active ingredient rasagiline, comprising: dissolving a pharmaceutically acceptable rasagiline salt in an aqueous solvent to obtain a rasagiline salt solution admixing a solid carrier with the rasagiline salt solution. In order to provide a process by means of which compositions in which the rasagiline has elevated stability are obtainable and the composition can correspondingly be stored for longer, it is proposed that the pH of the rasagiline salt solution be adjusted to a value of less than 3.5 by means of a pharmaceutically acceptable acid.
